Kamada (NASDAQ:KMDA) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Friday.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
A number of other analysts have also recently commented on the company. ValuEngine upgraded Kamada from a “sell” rating to a “hold” rating in a research report on Thursday. HC Wainwright restated a “buy” rating on shares of Kamada in a research report on Thursday. Chardan Capital initiated coverage on Kamada in a research report on Friday, February 2nd. They issued a “buy” rating and a $7.00 price target on the stock. Finally, Jefferies Group restated a “buy” rating and issued a $7.00 price target on shares of Kamada in a research report on Thursday, October 12th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $7.00.
Kamada (NASDAQ:KMDA) last posted its earnings results on Wednesday, February 7th. The biotechnology company reported $0.16 EPS for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.10. Kamada had a return on equity of 9.06% and a net margin of 6.71%. The business had revenue of $35.71 million for the quarter, compared to analysts’ expectations of $32.90 million. research analysts forecast that Kamada will post 0.16 EPS for the current fiscal year.
A number of hedge funds have recently modified their holdings of KMDA. Jane Street Group LLC acquired a new position in Kamada during the 3rd quarter worth approximately $112,000. Worth Venture Partners LLC acquired a new position in Kamada during the 3rd quarter worth approximately $246,000. Navellier & Associates Inc acquired a new position in Kamada during the 2nd quarter worth approximately $303,000. Analyst IMS Investment Management Services Ltd. increased its position in Kamada by 125.5% during the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after purchasing an additional 50,000 shares during the period. Finally, Vanguard Group Inc. increased its position in Kamada by 6.5% during the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after purchasing an additional 28,382 shares during the period. Hedge funds and other institutional investors own 6.26% of the company’s stock.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.